BINEX Co., Ltd. (KOSDAQ:053030)

South Korea · Delayed Price · Currency is KRW

7,320.00

-430.00 (-5.55%)

Jun 30, 2026, 3:30 PM KST

-52.71% (1Y)

Market Cap	233.12B -58.3%
Revenue (ttm)	164.00B +17.0%
Net Income	-12.86B
EPS	-403.67
Shares Out	31.85M
PE Ratio	n/a
Forward PE	46.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,004
Open	7,610.00
Previous Close	7,750.00
Day's Range	7,300.00 - 7,730.00
52-Week Range	6,720.00 - 19,200.00
Beta	0.66
Analysts	Buy
Price Target	12,550.00 (+71.45%)
Earnings Date	Aug 14, 2026

About BINEX

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The company engages in cell line and process development, and analytical method production development. It is also involved in cell cultivation and microbial fermentation modalities process production. In addition, the company offers chemical pharmaceutical products. BINEX Co., Ltd. was founded in 1957 and is headquartered in Busan, South Korea. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1957

Employees 667

Stock Exchange KOSDAQ

Ticker Symbol 053030

Full Company Profile

Financial Performance

In 2025, BINEX's revenue was 168.47 billion, an increase of 29.55% compared to the previous year's 130.05 billion. Losses were -3.23 billion, -90.80% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 053030 stock is "Buy." The 12-month stock price target is ₩12,550, which is an increase of 71.45% from the latest price.

Price Target

₩12,550

(71.45% upside)

Analyst Consensus: Buy

Stock Forecasts